Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("PHASE III TRIAL")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 2905

  • Page / 117
Export

Selection :

  • and

SELECTION OF APPROPRIATE STUDIES FOR PHASE III TRIALS OF RADIOSENSITIZERS = SELECTION DES ETUDES APPROPRIEES POUR LES ESSAIS EN PHASE II DES RADIOSENSIBILISATEURSMAOR MH; PETERS LJ.1983; INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS; ISSN 0360-3016; USA; DA. 1983; VOL. 9; NO 2; PP. 271; BIBL. 5 REF.Article

PIPERACILLIN SODIUM (A PHASE III CLINICAL TRIAL)MACBETH WAAG.1981; J. INT. MED. RES.; ISSN 0300-0605; GBR; DA. 1981; VOL. 9; NO 5; PP. 353-359; BIBL. 1 REF.Article

Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanomaMARKOVIC, Svetomir; SUMAN, Vera J; KROOK, James E et al.American journal of clinical oncology. 2002, Vol 25, Num 6, pp 552-556, issn 0277-3732, 5 p.Article

COMPARISON OF THE THERAPEUTIC RESPONSE OF PATIENTS WITH CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN RELAPSE TO VINDESINE VERSUS VINCRISTINE IN COMBINATION WITH PREDNISONE AND L-ASPARAGINASE: A PHASE III TRIALANDERSON J; KRIVIT W; CHILCOTE R et al.1981; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1981; VOL. 65; NO 11-12; PP. 1015-1019; BIBL. 11 REF.Article

COMBINATION CHEMOTHERAPY FOR SOFT-TISSUE SARCOMAS: A PHASE III STUDYCRUZ AB JR; THAMES EA JR; AUST JB et al.1979; J. SURG. ONCOL.; USA; DA. 1979; VOL. 11; NO 4; PP. 313-323; BIBL. 13 REF.Article

CONTINUATION OF PHASE II STUDY OF 1-(4-AMINO-2-METHYLPYRIMIDINE-5-YL)-METHYL-3-(2-CHLOROETHYL)-3-NITROSO UREA HYDROCHLORIDE (ACNU)SAITO T.1980; RECENT RESULTS CANCER RES.; DEU; DA. 1980; VOL. 70; PP. 91-106; BIBL. 11 REF.Conference Paper

FASE II-III DE ESTUDIO DEL CIS-DIAMINO DICLOROPLATINO (CISPLATINO) = ESSAI PHASE II-III DU CIS-DIAMINODICHLOROPLATINE (CISPLATINE)CORTES FUNES H; MOYANO A.1981; MED. CLIN. (BARC.); ISSN 0025-7753; ESP; DA. 1981; VOL. 76; NO 9; PP. 388-395; ABS. ENG; BIBL. 51 REF.Article

MANAGEMENT OF TRIALS IN THE DEVELOPMENT OF CANCER CHEMOTHERAPY.WILLIAMS CJ; CARTER SK.1978; BRIT. J. CANCER; GBR; DA. 1978; VOL. 37; NO 3; PP. 434-447; BIBL. 24 REF.Article

LE PROGRES THERAPEUTIQUE. ANALYSE CRITIQUE DES ETUDES CLINIQUES CONTROLEES ET NON CONTROLEESALBERTO P.1978; SCHWEIZ. MED. WSCHR.; CHE; DA. 1978; VOL. 108; NO 37; PP. 1433-1437; ABS. ENG; BIBL. 16 REF.Article

CLINICAL TRIALSOF NEW DRUGS.DOLLERY CT; WADE OL; TURNER P et al.1977; J. R. COLL. PHYSICIANS LONDON; G.B.; DA. 1977; VOL. 11; NO 3; PP. 226-233; BIBL. 1 REF.Article

CLINICAL TRIALS IN CANCER CHEMOTHERAPY.CARTER SK.1977; CANCER; U.S.A.; DA. 1977; VOL. 40; NO 1, SUPPL.; PP. 544-557; BIBL. 1 P. 1/2Article

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404PRADOS, Michael D; SEIFERHELD, Wendy; GREENBERG, Harry S et al.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 4, pp 1147-1152, issn 0360-3016, 6 p.Article

On the design of the phase III drug trial. The example of rheumatoid arthritisHADLER, N. M; GILLINGS, D. B.Arthritis and rheumatism. 1983, Vol 26, Num 11, pp 1354-1361, issn 0004-3591Article

The ethical position of the attending physician in phase III of clinical investigationsVON EICKSTEDT, K.-W.International journal of clinical pharmacology, therapy and toxicology (1980). 1983, Vol 21, Num 10, pp 529-534, issn 0174-4879Article

MR angiography of aortoiliac occlusive disease : A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325GOYEN, Mathias; EDELMAN, Mark; KENT YUCEL, E et al.Radiology. 2005, Vol 236, Num 3, pp 825-833, issn 0033-8419, 9 p.Article

What are the reasons for negative phase III trials of molecular-target-based drugs?SAIJO, Nagahiro.Cancer science. 2004, Vol 95, Num 10, pp 772-776, issn 1347-9032, 5 p.Article

Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIPEMBERTON, Trevor J; CHAOLONG WANG; LI, Jun Z et al.American journal of human genetics. 2010, Vol 87, Num 4, pp 457-464, issn 0002-9297, 8 p.Article

The importance of reporting patient recruitment details in phase III trialsWRIGHT, James R; BOUMA, Sarah; DAYES, Ian et al.Journal of clinical oncology. 2006, Vol 24, Num 6, pp 843-847, issn 0732-183X, 5 p.Article

Clinical development of dietary supplements: The perils of starting at phase IIIBERMAN, Josh.Fitoterapia (Milano). 2011, Vol 82, Num 1, pp 80-84, issn 0367-326X, 5 p.Article

Phase III Clinical Trial Development: A Process of Chutes and LaddersDILTS, David M; CHENG, Steven K; CRITES, Joshua S et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5381-5389, issn 1078-0432, 9 p.Article

Using a drug before the risks and benefits are known from a phase 3 clinical trial : Thoughts on compassionMILLER, Joan W.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1029-1031, issn 0003-9950, 3 p.Article

Disclosure of competing financial interests and role of sponsors in phase III cancer trialsTUECH, Jean-Jacques; MOUTEL, Grégoire; PESSAUX, Patrick et al.European journal of cancer (1990). 2005, Vol 41, Num 15, pp 2237-2240, issn 0959-8049, 4 p.Article

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5197-5201, issn 0732-183X, 5 p.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MSFREEDMAN, M. S; BAR-OR, A; FERENCZI, L et al.Neurology. 2011, Vol 77, Num 16, pp 1551-1560, issn 0028-3878, 10 p.Article

  • Page / 117